| Primary |
| Chronic Obstructive Pulmonary Disease |
32.9% |
| Asthma |
13.4% |
| Emphysema |
12.5% |
| Dyspnoea |
8.7% |
| Hypertension |
8.4% |
| Prophylaxis |
2.8% |
| Systemic Lupus Erythematosus |
2.3% |
| Atrial Fibrillation |
2.1% |
| Blood Cholesterol Increased |
2.0% |
| Gastrooesophageal Reflux Disease |
1.9% |
| Hypothyroidism |
1.6% |
| Cough |
1.5% |
| Diabetes Mellitus |
1.5% |
| Hiv Infection |
1.5% |
| Supplementation Therapy |
1.4% |
| Cardiac Disorder |
1.3% |
| Anxiety |
1.1% |
| Bronchitis |
1.1% |
| Bronchitis Chronic |
1.1% |
| Depression |
0.9% |
|
| Drug Ineffective |
21.2% |
| Dyspnoea |
16.8% |
| Throat Irritation |
7.5% |
| Wheezing |
4.9% |
| Dry Mouth |
4.4% |
| Dysphonia |
4.4% |
| Tongue Coated |
4.0% |
| Vision Blurred |
4.0% |
| Drug Effect Decreased |
3.5% |
| Tremor |
3.5% |
| Dysgeusia |
3.1% |
| Oropharyngeal Pain |
3.1% |
| Urticaria |
3.1% |
| Weight Decreased |
3.1% |
| Pneumonia |
2.7% |
| Death |
2.2% |
| Malaise |
2.2% |
| Speech Disorder |
2.2% |
| Throat Tightness |
2.2% |
| Alopecia |
1.8% |
|
| Secondary |
| Chronic Obstructive Pulmonary Disease |
21.6% |
| Dyspnoea |
20.4% |
| Asthma |
13.2% |
| Emphysema |
12.8% |
| Bronchitis Chronic |
5.1% |
| Hypertension |
3.8% |
| Systemic Lupus Erythematosus |
3.8% |
| Supplementation Therapy |
2.9% |
| Blood Cholesterol Increased |
1.9% |
| Cough |
1.7% |
| Product Used For Unknown Indication |
1.7% |
| Wheezing |
1.7% |
| Rhinorrhoea |
1.6% |
| Gastrooesophageal Reflux Disease |
1.4% |
| Laxative Supportive Care |
1.4% |
| Bronchitis |
1.3% |
| Atrial Fibrillation |
1.0% |
| Blood Pressure Abnormal |
1.0% |
| Cardiac Failure Congestive |
1.0% |
| Bronchospasm |
0.8% |
|
| Drug Ineffective |
22.9% |
| Urticaria |
9.4% |
| Hypersensitivity |
8.3% |
| Aphonia |
6.3% |
| Oropharyngeal Pain |
5.2% |
| Adverse Drug Reaction |
4.2% |
| Incorrect Route Of Drug Administration |
4.2% |
| Pneumonia |
4.2% |
| Productive Cough |
4.2% |
| Swelling Face |
4.2% |
| Weight Decreased |
4.2% |
| Medication Error |
3.1% |
| Sudden Onset Of Sleep |
3.1% |
| Throat Irritation |
3.1% |
| Weight Increased |
3.1% |
| Anaphylactic Reaction |
2.1% |
| Dysgeusia |
2.1% |
| Dysphonia |
2.1% |
| Dyspnoea |
2.1% |
| Glossodynia |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.3% |
| Chronic Obstructive Pulmonary Disease |
17.3% |
| Dyspnoea |
14.6% |
| Asthma |
10.7% |
| Drug Use For Unknown Indication |
7.3% |
| Emphysema |
6.5% |
| Hypertension |
3.5% |
| Bronchitis Chronic |
2.1% |
| Pain |
1.6% |
| Supplementation Therapy |
1.6% |
| Multiple Allergies |
1.5% |
| Cardiac Disorder |
1.2% |
| Hypersensitivity |
1.2% |
| Rheumatoid Arthritis |
1.2% |
| Hepatitis C |
1.1% |
| Nasal Congestion |
1.1% |
| Cardiac Failure Congestive |
1.0% |
| Plasma Cell Myeloma |
0.8% |
| Blood Cholesterol Increased |
0.7% |
| Gastrooesophageal Reflux Disease |
0.7% |
|
| Drug Ineffective |
19.5% |
| Dyspnoea |
9.2% |
| Pneumonia |
8.0% |
| Vomiting |
8.0% |
| Adverse Drug Reaction |
6.9% |
| Asthma |
4.6% |
| Hypersensitivity |
4.6% |
| Tremor |
4.6% |
| Vision Blurred |
4.6% |
| Dry Mouth |
3.4% |
| Upper Respiratory Tract Infection |
3.4% |
| Urinary Tract Infection |
3.4% |
| Weight Decreased |
3.4% |
| Cardiac Failure Congestive |
2.3% |
| Chronic Obstructive Pulmonary Disease |
2.3% |
| Cough |
2.3% |
| Drug Intolerance |
2.3% |
| Glaucoma |
2.3% |
| Haemoglobin Decreased |
2.3% |
| Headache |
2.3% |
|
| Interacting |
| Chronic Obstructive Pulmonary Disease |
50.0% |
| Blood Cholesterol Increased |
16.7% |
| Hypertension |
16.7% |
| Smoking Cessation Therapy |
16.7% |
|
|
